Compare Kyndryl Holdings Inc (KD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs TG Therapeutics Inc — how do they compare? Kyndryl Holdings Inc trades at $12.15 (market cap $2.69B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 3.1× Kyndryl Holdings Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | TGTX | |
|---|---|---|
Market Cap | $2.69B | $8.26B |
Sector | Technology | Health |
52-Week High | $39.47 | $59.06 |
52-Week Low | $10.59 | $26.39 |
Enterprise Value | $5.03B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KD trades at $12.19, up 0.33% on the day, with a neutral technical signal. The company reported revenue of $15.06B in 2025, with net income turning positive to $252M after three years of losses. Recent news includes a partnership with Microsoft for sovereignty solutions and ongoing legal investigations into officers and directors.
The outlook is mixed; improving profitability and a low P/E of 14.38 suggest value, but recent earnings misses and legal scrutiny pose risks. Analyst consensus is a $14.00 price target with a hold rating, indicating cautious optimism amid transformation efforts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
